Processing

Please wait...

Settings

Settings

Goto Application

Offices all Languages Stemming false Single Family Member true Include NPL false
RSS feed can only be generated if you have a WIPO account

Save query

A private query is only visible to you when you are logged-in and can not be used in RSS feeds

Query Tree

Refine Options

Offices
All
Specify the language of your search keywords
Stemming reduces inflected words to their stem or root form.
For example the words fishing, fished,fish, and fisher are reduced to the root word,fish,
so a search for fisher returns all the different variations
Returns only one member of a family of patents
Include Non-Patent literature in results

Full Query

IC:C12P

Side-by-side view shortcuts

General
Go to Search input
CTRL + SHIFT +
Go to Results (selected record)
CTRL + SHIFT +
Go to Detail (selected tab)
CTRL + SHIFT +
Go to Next page
CTRL +
Go to Previous page
CTRL +
Results (First, do 'Go to Results')
Go to Next record / image
/
Go to Previous record / image
/
Scroll Up
Page Up
Scroll Down
Page Down
Scroll to Top
CTRL + Home
Scroll to Bottom
CTRL + End
Detail (First, do 'Go to Detail')
Go to Next tab
Go to Previous tab

Analysis

1.WO/2023/000618BACILLUS XIAOXIENSIS AND APPLICATION THEREOF
WO 26.01.2023
Int.Class C12N 1/20
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
1Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
20Bacteria; Culture media therefor
Appl.No PCT/CN2021/143099 Applicant JIANGNAN UNIVERSITY Inventor LI, Caiming
Provided are a Bacillus xiaoxiensis STB08 for producing a β-cyclodextrin glucosyltransferase, and a method for preparing the β-cyclodextrin glucosyltransferase by using the Bacillus xiaoxiensis STB08. Also provided is the β-cyclodextrin glucosyltransferase derived from the Bacillus xiaoxiensis STB08, the β-cyclodextrin glucosyltransferase has an amino acid sequence as shown in SEQ ID NO.1, and has a nucleotide sequence of a coding gene thereof as shown in SEQ ID NO.2.
2.WO/2023/004293RECOMBINANT MICROORGANISMS AND USES THEREFOR
WO 26.01.2023
Int.Class C12N 15/74
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
74Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
Appl.No PCT/US2022/073855 Applicant LANZATECH, INC. Inventor FACKLER, Nicholas, Alexander
The disclosure provides genetically engineered C1-fixing microorganisms capable of producing nanobodies. Additionally, the disclosure provides engineered microorganisms comprising one or more disrupted genes to strategically divert carbon flux away from nonessential or undesirable products towards products and/or co-products of interest. The disclosure enables co-production of useful chemicals from gaseous substrates.
3.WO/2023/004152COMPOSITIONS, METHODS, AND ARTICLES COMPRISING COCAINE ESTERASE FOR DETOXIFYING AN ORGANOPHOSPHATE-BASED AGENT
WO 26.01.2023
Int.Class A62D 3/02
AHUMAN NECESSITIES
62LIFE-SAVING; FIRE-FIGHTING
DCHEMICAL MEANS FOR EXTINGUISHING FIRES; PROCESSES FOR MAKING HARMFUL CHEMICAL SUBSTANCES HARMLESS, OR LESS HARMFUL, BY EFFECTING A CHEMICAL CHANGE; COMPOSITION OF MATERIALS FOR COVERINGS OR CLOTHING FOR PROTECTING AGAINST HARMFUL CHEMICAL AGENTS; COMPOSITION OF MATERIALS FOR TRANSPARENT PARTS OF GAS-MASKS, RESPIRATORS, BREATHING BAGS OR HELMETS; COMPOSITION OF CHEMICAL MATERIALS FOR USE IN BREATHING APPARATUS
3Processes for making harmful chemical substances harmless, or less harmful, by effecting a chemical change in the substances
02by biological methods, i.e. processes using enzymes or microorganisms
Appl.No PCT/US2022/038073 Applicant FOUR WINDS BIOTHERAPEUTICS, INC. Inventor VILLANUEVA, Nicolas
Disclosed herein are compositions, methods, and articles of personal protective equipment for use in detoxifying an organophosphate-based agent, wherein the compositions, methods, and articles comprise contacting the organophosphate-based agent with a cocaine esterase, wherein the contacting detoxifies the organophosphate-based agent.
4.WO/2023/003972CANCER TREATMENT COMBINATIONS
WO 26.01.2023
Int.Class A61K 45/06
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
45Medicinal preparations containing active ingredients not provided for in groups A61K31/-A61K41/132
06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
Appl.No PCT/US2022/037755 Applicant VIRACTA SUBSIDIARY, INC. Inventor ROJKJAER, Lisa
Described herein is a method of treating a cancer or tumor in an individual, the method comprising administering to the individual afflicted with the cancer or tumor an effective amount of: a) nanatinostat; b) a nucleoside analog; c) and a checkpoint inhibitor antagonist.
5.WO/2023/002952PROTEASE-MEDIATED TARGET SPECIFIC CYTOKINE DELIVERY USING FUSION POLYPEPTIDE
WO 26.01.2023
Int.Class C07K 19/00
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
19Hybrid peptides
Appl.No PCT/JP2022/027893 Applicant CHUGAI SEIYAKU KABUSHIKI KAISHA Inventor CHICHILI, Vishnu Priyanka Reddy
The present invention relates to fusion proteins comprising a ligand binding domain, a protease cleavage site, and a ligand moiety. The fusion proteins of the invention comprise a ligand binding domain, a ligand moiety, and a protease cleavage site that, when activated by cleavage by a protease, restores biological activity of the ligand. The invention also relates to methods of producing the fusion proteins, their uses and pharmaceutical compositions comprising said fusion proteins. The present invention also relates to a method of reducing the association between heavy chain variable domain (VH) and light chain variable domain (VL) within the ligand binding domain that promotes dissociation of one from the other. The present disclosure provides fusion proteins in which the ligand is fused to the C-terminus of the constant region, or the N-terminus of the ligand binding domain.
6.WO/2023/000492STRAIN FOR SYNTHESIZING EXOPOLYSACCHARIDE BY MEANS OF FERMENTING WHEAT BRAN
WO 26.01.2023
Int.Class C12N 1/20
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
1Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
20Bacteria; Culture media therefor
Appl.No PCT/CN2021/120703 Applicant BRIGHT DAIRY & FOOD CO., LTD Inventor HAN, Jin
Provided in the present invention is a strain of Paenibacillus sp. for synthesizing an exopolysaccharide by means of fermenting wheat bran, and the deposit number of the strain is CGMCC NO. 8333; the exopolysaccharide synthesized has a weight-average molecular weight of 300,800-451,200 daltons, and is an acidic heteropolysaccharide composed of glucuronic acid, glucose and fucose in a molar ratio of (1.55-1.60):1:(1.63-1.72); and a main chain of the exopolysaccharide is composed of 1,3-linked glucose residues, 1,3-linked fucose residues, 1,3,4-linked fucose residues and 1,4-linked glucuronic acid residues, a branch point is located at an O-4 position of the 1,3,4-linked fucose residue, and a branch chain is composed of terminal-linked glucuronic acid residues and the exopolysaccharide is composed of repeating structural units as shown in formula I. In addition, the exopolysaccharide also has a certain immunoregulation effect, and has good application prospects in food, medicine and related fields.
7.WO/2023/004302CELL-FREE BIOPRODUCTION OF B-CRYPTOXANTHIN AND ZEAXANTHIN
WO 26.01.2023
Int.Class C12P 23/00
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
PFERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
23Preparation of compounds containing a cyclohexene ring having an unsaturated side chain containing at least ten carbon atoms bound by conjugated double bonds, e.g. carotenes
Appl.No PCT/US2022/073874 Applicant DEBUT BIOTECHNOLOGY, INC. Inventor WAGNER, Drew
A cell-free system is provided to produce β-cryptoxanthin and zeaxanthin from β-carotene. β-carotene is added to a reaction mixture comprising a β-carotene hydroxylase enzyme (CrtZ). The reaction mixture may be aqueous and may comprise a co-solvent, e.g., an organic co-solvent, such as THF.
8.WO/2023/003118NOVEL METABOLIC PATHWAY FOR PRODUCING ITACONIC ACID AND METHOD FOR PRODUCING ITACONIC ACID USING SAME
WO 26.01.2023
Int.Class C12N 15/70
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
70Vectors or expression systems specially adapted for E. coli
Appl.No PCT/KR2022/002865 Applicant POSTECH RESEARCH AND BUSINESS DEVELOPMENT FOUNDATION Inventor JUNG, Gyoo Yeol
The present invention relates to a novel metabolic pathway for producing itaconic acid and a recombinant microorganism, for producing itaconic acid, into which the metabolic pathway is introduced. It has been confirmed that the recombinant microorganism, for producing itaconic acid, into which the novel itaconic acid metabolic pathway is introduced, according to the present invention, significantly increases the production and yield of itaconic acid. In addition, as the recombinant microorganism for producing itaconic acid of the present invention uses an intermediate material of glycolysis rather than an intermediate material of the TCA cycle, the recombinant microorganism can further increase the production yield of itaconic acid through further improvement. Accordingly, the novel metabolic pathway for producing itaconic acid and the recombinant microorganism into which the metabolic pathway is introduced can increase the economic feasibility of itaconic acid, and thus can be variously used in industrial fields for synthetic resins, latexes, food additives, and the like in which itaconic acid is utilized.
9.WO/2023/004125GENERATION OF LARGE PROTEINS BY CO-DELIVERY OF MULTIPLE VECTORS
WO 26.01.2023
Int.Class C12N 15/86
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
79Vectors or expression systems specially adapted for eukaryotic hosts
85for animal cells
86Viral vectors
Appl.No PCT/US2022/038032 Applicant UNIVERSITY OF WASHINGTON Inventor CHAMBERLAIN, Jeffrey S.
Provided herein are methods and compositions for delivering large proteins to a subject in need thereof for treatment of a disease or disorder. In certain embodiments, the methods and compositions described herein are useful in the delivery of large proteins to subjects using a protein expression system comprising at first and second AAV vector for the treatment of muscular or neuromuscular disease or disorders.
10.WO/2023/002506COMPOSITIONS OF SOPHOROLIPIDS FOR POTENTIAL USE IN THE TREATMENT OF TUBERCULOSIS AND MULTIDRUG RESISTANT TUBERCULOSIS
WO 26.01.2023
Int.Class A61K 31/545
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
54having six-membered rings with at least one nitrogen and at least one sulfur as the ring hetero atoms, e.g. sulthiame
542ortho- or peri-condensed with heterocyclic ring systems
545Compounds containing 5-thia-1-azabicyclo octane ring systems, i.e. compounds containing a ring system of the formula , e.g. cephalosporins, cefaclor, cephalexine
Appl.No PCT/IN2022/050650 Applicant GODREJ INDUSTRIES LTD (CHEMICALS) Inventor GHARAT, Sandeep Dattatray
The present invention discloses compositions comprising Sophorolipids, having anti-tubercular activity for potential use in the treatment of tuberculosis and multidrug resistant tuberculosis. The invention also discloses compositions comprising Sophorolipids and its compatibility with standard anti-tuberculosis drugs for potential use in treatment of tuberculosis and multi-drug resistant tuberculosis as a part of multi-drug regimen.